Mallinckrodt (MNK) Mentioned Cautiously at Citron Research

November 16, 2016 11:39 AM EST

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

(Updated - November 16, 2016 11:42 AM EST)

Mallinckrodt (NYSE: MNK) was mentioned cautiously at Citron Research. The report said a newly published Medicare dashboard proves that:

  • "1. As insurance companies have clamped down on reimbursement, tax-inverted Mallinckrodt has dug deeper into the pockets of taxpayer-funded Medicare to peddle its medically unproven Acthar
  • 2. The CEO of MNK has committed FRAUD by lying to the investing public about the company‚Äôs dependence on the Medicare system.
  • 3. Acthar is now THE MOST EXPENSIVE drug reimbursed by Medicare.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Short Sales, Trader Talk

Related Entities

Citron Research

Add Your Comment